Form 4: Health In Tech CSO Receives Performance-Based Stock Grant

Chief Strategy Officer Jonathan Del Lockett was granted 50,000 restricted shares of Class A Common Stock tied to performance milestones.

Summary

• Jonathan Del Lockett, Chief Strategy Officer of Health In Tech, Inc., received a grant of 50,000 restricted shares of Class A Common Stock.
• The grant is subject to performance-based milestones.
• 20,000 shares vest in equal monthly installments over 12 months starting July 1, 2026, contingent on the first milestone.
• 30,000 shares vest in equal monthly installments over 12 months starting August 15, 2026, contingent on the second milestone.
• Following this transaction, the reporting person holds 143,539 total shares, consisting of 78,985 unrestricted and 64,554 restricted shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing regarding executive compensation, reflecting standard corporate governance rather than a material change in company financial health.

Positives

• Alignment of executive compensation with specific performance-based milestones.
• Incentivizes long-term strategic growth through equity-based vesting.

Negatives

• Potential for share dilution if performance milestones are met and new shares are issued.
• Restricted nature of the shares limits immediate liquidity for the executive.

Risks

• Failure to achieve performance milestones will result in the forfeiture of the 50,000 granted shares.
• Market volatility affecting the value of equity compensation.

Future Outlook

The company expects the executive to meet specific performance milestones to trigger the vesting of the 50,000 restricted shares over the next 12-15 months.

Management Comments

• The grant is issued pursuant to the Health In Tech Equity Incentive Plan.

Industry Context

StockSavvy.ai notes that performance-based equity grants are standard practice in the health-tech sector to align executive incentives with operational success and shareholder value creation.

Comparison to Industry Standards

• The use of performance-based vesting schedules is consistent with governance best practices for publicly traded technology and healthcare companies.
• The 12-month vesting period is a standard retention mechanism for executive officers.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential dilution if performance targets are met.
• Executive: Increased alignment with company performance goals.

Next Steps

• Achievement of performance milestones by July 1, 2026, and August 15, 2026.
• Commencement of vesting schedules for the granted shares.

Key Dates

Keywords

Health In Tech, HIT, Insider Trading, Form 4, Equity Incentive Plan, Executive Compensation